IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity

Oncolytic virotherapies have shown excellent promise in a variety of cancers by promoting antitumor immunity. However, the effects of oncolytic virus-mediated type I interferon (IFN-I) production on antitumor immunity remain unclear. Recent reports have highlighted immunosuppressive functions of IFN...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Sayes, Nader, Walsh, Scott, Vito, Alyssa, Reihani, Amir, Ask, Kjetil, Wan, Yonghong, Mossman, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971726/
https://www.ncbi.nlm.nih.gov/pubmed/35399605
http://dx.doi.org/10.1016/j.omto.2022.03.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971726/
https://www.ncbi.nlm.nih.gov/pubmed/35399605
http://dx.doi.org/10.1016/j.omto.2022.03.006

Ejemplares similares